Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)

Jie Cui; Chase W. Kessinger; Harkamal S. Jhajj; Madeleine S. Grau; Sanjay Misra; Peter Libby; Jason R. McCarthy; Farouc A. Jaffer

doi:10.1681/ASN.2020070950

Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)

Jie Cui
, Chase W. Kessinger
, Harkamal S. Jhajj
, Madeleine S. Grau
, Sanjay Misra
, Peter Libby
, Jason R. McCarthy
, Farouc A. Jaffer

Research output: Contribution to journal › Comment/debate

Abstract

Dr. Peter Libby inadvertently omitted the following statement from his disclosures: Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Original language	English
Pages (from-to)	2230
Number of pages	1
Journal	Journal of the American Society of Nephrology
Volume	31
Issue number	9
DOIs	https://doi.org/10.1681/ASN.2020070950
State	Published - Sep 2020
Externally published	Yes

Access to Document

10.1681/ASN.2020070950

Fingerprint

Dive into the research topics of 'Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)'. Together they form a unique fingerprint.

Cite this

Cui, J., Kessinger, C. W., Jhajj, H. S., Grau, M. S., Misra, S., Libby, P., McCarthy, J. R., & Jaffer, F. A. (2020). Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612). Journal of the American Society of Nephrology, 31(9), 2230. https://doi.org/10.1681/ASN.2020070950

Cui, Jie ; Kessinger, Chase W. ; Jhajj, Harkamal S. et al. / Erratum : Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612). In: Journal of the American Society of Nephrology. 2020 ; Vol. 31, No. 9. pp. 2230.

@article{e18db8bdf0ab4cc9abdbcb00cb454a6b,

title = "Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)",

abstract = "Dr. Peter Libby inadvertently omitted the following statement from his disclosures: Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.",

author = "Jie Cui and Kessinger, \{Chase W.\} and Jhajj, \{Harkamal S.\} and Grau, \{Madeleine S.\} and Sanjay Misra and Peter Libby and McCarthy, \{Jason R.\} and Jaffer, \{Farouc A.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 by the American Society of Nephrology",

year = "2020",

month = sep,

doi = "10.1681/ASN.2020070950",

language = "English",

volume = "31",

pages = "2230",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "Wolters Kluwer Health",

number = "9",

}

Cui, J, Kessinger, CW, Jhajj, HS, Grau, MS, Misra, S, Libby, P, McCarthy, JR & Jaffer, FA 2020, 'Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)', Journal of the American Society of Nephrology, vol. 31, no. 9, pp. 2230. https://doi.org/10.1681/ASN.2020070950

Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612). / Cui, Jie; Kessinger, Chase W.; Jhajj, Harkamal S. et al.
In: Journal of the American Society of Nephrology, Vol. 31, No. 9, 09.2020, p. 2230.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612)

AU - Cui, Jie

AU - Kessinger, Chase W.

AU - Jhajj, Harkamal S.

AU - Grau, Madeleine S.

AU - Misra, Sanjay

AU - Libby, Peter

AU - McCarthy, Jason R.

AU - Jaffer, Farouc A.

PY - 2020/9

Y1 - 2020/9

N2 - Dr. Peter Libby inadvertently omitted the following statement from his disclosures: Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

AB - Dr. Peter Libby inadvertently omitted the following statement from his disclosures: Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies. Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

UR - https://www.scopus.com/pages/publications/85090107804

U2 - 10.1681/ASN.2020070950

DO - 10.1681/ASN.2020070950

M3 - Comment/debate

C2 - 32868375

AN - SCOPUS:85090107804

SN - 1046-6673

VL - 31

SP - 2230

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 9

ER -

Cui J, Kessinger CW, Jhajj HS, Grau MS, Misra S, Libby P et al. Erratum: Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula (Journal of the American Society of Nephrology (2020) 31 (931-945) DOI: 10.1681/ASN.2019060612). Journal of the American Society of Nephrology. 2020 Sep;31(9):2230. doi: 10.1681/ASN.2020070950